Urologic Care for the APP Industry Sponsored Lunch (Non-CME)
Sunday, May 17, 2026 12:30 PM to 1:45 PM · 1 hr. 15 min. (America/New_York)
Ballroom B
Detail
APP/Allied Health
Information
A Non-CME Lunch Symposium supported by Astellas Pharma US, Inc. and Pfizer Oncology for APPs: Treatment Intensification with XTANDI (Enzalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer & Nonmetastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence at High Risk for Metastasis.